Exploratory Program
Myelofibrosis
Pre-clinicalActive
Key Facts
About Cellarity
Cellarity is a private, AI-driven biotech founded in 2017 that is shifting the drug discovery paradigm from single-target to cell-state-focused therapeutics. Its core technology combines high-dimensional single-cell data with AI models to identify novel biological pathways and design oral compounds that correct dysfunctional cellular networks. The company has advanced its first candidate, CLY-124 for sickle cell disease, into clinical development and has established a strategic partnership with Novo Nordisk in metabolic disease, validating its platform's potential.
View full company profileTherapeutic Areas
Other Myelofibrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Tasquinimod | Active Biotech | Phase Ib/IIa |
| Zavabresib (OPN-2853) | Opna Bio | Phase 1 |
| GB2064 | Galecto | Phase 2 |
| Myelofibrosis Program | Sequantrix | Pre-clinical |
| Jakafi (ruxolitinib) | Incyte | Marketed |
| KER-050 (Eltritercept) | Keros Therapeutics | Phase 2 |
| Selinexor | Karyopharm Therapeutics | Phase 3 |